Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.
A team of researchers in Italy have published a study suggesting that rather than platelets, neutrophils could be playing the lead role in thrombotic complications associated with COVID-19.
A potentially valuable new study discusses the role of lipids in the hyper-inflammatory phenomena that take place within the lungs of patients with severe or critical COVID-19. Involving a large variety of specialized lipids with biological activity, this process includes the generation and release of pro and anti-inflammatory lipids.
News-Medical spoke to researchers about their latest research into beta-blockers, and how they could potentially be used to treat COVID-19.
The international trialists Professors Lars Wallentin, Jan van Gijn, Bo Norrving and Tom Meade were recognized for their work on low-dose aspirin, with the presentation of the International Aspirin Foundation Senior Science Award.
The University of Illinois Chicago will conduct three clinical trials for studying blood clot prevention in patients with COVID-19.
Patients with plaque build-up in their arteries, who suffered a transient ischemic attack (TIA) or a minor ischemic stroke, also called a warning stroke, and were treated with the newer blood thinner ticagrelor plus aspirin were 27% less likely to have another stroke within 30 days, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020.
Heart attacks, strokes and other cardiovascular incidents can be cut by 20 to 40 per cent through use of a polypill which combines three blood pressure medications and a lipid lowering medication taken alone or with aspirin.
A one-month treatment of dual anti-platelet therapy is safe and as effective as a longer duration of therapy at preventing cardiac events in patients one year after stent placement, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020.
The use of the more potent antiplatelet medication ticagrelor was not superior to clopidogrel in the reduction of the rate of heart attack or severe complications among people undergoing an elective procedure to open a blocked artery, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020.
A single, daily pill combining blood pressure and cholesterol medications, along with the addition of a daily dose of aspirin, reduced cardiovascular disease events in people at risk for heart disease, according to late-breaking research presented today in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2020.
Patients with cancer have multiple treatment options available to them today, but each has its drawbacks. Chemotherapy kills rapidly dividing cancer cells, but it also damages healthy cells in the body and often does not effectively prevent tumor metastasis or disease recurrence.
Now, in new research, the everyday painkiller aspirin will be evaluated as a potential treatment for COVID-19 in one of the United Kingdom’s most significant trials, aiming to evaluate whether it can reduce the risk of blood clots in infected people.
An X-ray test commonly used to assess hardening of the arteries could help doctors decide whether the benefits of taking aspirin to prevent a first heart attack or stroke outweigh the risks of bleeding from its use, UT Southwestern research suggests.
Hospitalized COVID-19 patients who were taking a daily low-dose aspirin to protect against cardiovascular disease had a significantly lower risk of complications and death compared to those who were not taking aspirin, according to a new study led by researchers at the University of Maryland School of Medicine.
The U.S. Food and Drug Administration announced today in a Drug Safety Communication that it is requiring labeling changes for nonsteroidal anti-inflammatory drugs (NSAIDs).
A pharmacist-led, new digital intervention that improves patient safety when prescribing medication in general practice reduced rates of hazardous prescribing by more than 40 per cent, 12 months after it had been introduced to 43 GP practices in Salford, finds a new study.
Women aged 50 or younger who suffer a heart attack are more likely than men to die over the following 11 years, according to a new study published today (Wednesday) in the European Heart Journal.
More than half of older patients hospitalized for heart failure, a progressive condition in which the heart doesn't pump blood as well as it should, are discharged from the hospital with prescriptions for 10 or more medications, according to new research published today in Circulation: Heart Failure, an American Heart Association journal.
A study out of University Hospitals found that removing the cost barrier for coronary artery calcium (CAC) screening resulted in an immediate increase in utilization of the test.
Combined use of aspirin, statins, and metformin is associated with decreased lung cancer incidence and mortality, according to a study published in the Journal of Thoracic Oncology.